Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Schrödinger, Inc. is a life sciences and software company that develops physics-based computational platforms to accelerate drug discovery and materials science research. The company operates at the intersection of biotechnology, pharmaceuticals, and advanced scientific software, providing tools that enable researchers to model, simulate, and predict molecular behavior with high precision. Its core value proposition is reducing the time, cost, and failure rates associated with traditional experimental approaches in drug development.
The company’s primary revenue drivers are its Software business, which licenses its computational chemistry and molecular modeling platforms, and its Drug Discovery business, which applies those platforms to develop proprietary and partnered therapeutic candidates. Schrödinger serves pharmaceutical companies, biotechnology firms, academic institutions, and industrial research organizations. Founded in 1990, the company was built around academic advances in computational chemistry and has evolved from a pure software provider into a hybrid platform company with an integrated drug discovery pipeline, culminating in its public listing in 2020.
Business Operations
Schrödinger operates through two primary business segments: Software and Drug Discovery. The Software segment generates revenue through subscription-based licensing of its computational platforms, including solutions for molecular modeling, drug design, and materials science, as well as professional services and training. These tools are used for structure-based drug design, molecular dynamics, and predictive simulations across both life sciences and materials applications.
The Drug Discovery segment focuses on discovering and developing novel therapeutic candidates, primarily in oncology and immunology, using Schrödinger’s proprietary platform. Revenue is generated through collaboration agreements, upfront and milestone payments, and potential royalties, as well as internally advancing wholly owned programs. The company conducts operations in both domestic and international markets and maintains a combination of in-house research capabilities and external collaborations. Schrödinger controls proprietary computational technologies and owns or partially owns drug candidates through subsidiaries and joint research arrangements.
Strategic Position & Investments
Schrödinger’s strategy centers on leveraging its computational platform as a scalable engine for both software licensing growth and differentiated drug discovery. Growth initiatives include expanding enterprise software adoption among large pharmaceutical customers, increasing penetration in materials science, and advancing its internal therapeutic pipeline into later-stage development. The company has emphasized reinvesting software cash flows into drug discovery to create long-term value.
Schrödinger has made targeted acquisitions and investments to enhance its platform capabilities, including acquiring XTAL BioStructures, Inc. to strengthen its structural biology and experimental data generation. It also maintains equity stakes and collaborative relationships in select biotechnology ventures that use its platform. Emerging focus areas include physics-based machine learning, cloud-native simulation tools, and applications of computational modeling beyond pharmaceuticals, such as energy storage and advanced materials.
Geographic Footprint
Schrödinger is headquartered in the United States, with its principal executive offices in New York City. The company has a significant operational presence across North America and Europe, with research, development, and commercial teams supporting global customers and partners.
Internationally, Schrödinger operates offices and research facilities in Europe and maintains a growing footprint in Asia, serving multinational pharmaceutical companies and academic institutions. Its software platforms are used globally, and its drug discovery collaborations often involve cross-border research and development activities, giving the company broad international influence despite a relatively concentrated physical footprint.
Leadership & Governance
Schrödinger was co-founded by William L. Goddard III, whose academic work in computational chemistry helped shape the company’s foundational technology. The leadership team combines expertise in software engineering, life sciences, and pharmaceutical development, with a strategic vision centered on integrating physics-based modeling with experimental and clinical workflows.
Key executives include:
- Ramsey Homsany – President and Chief Executive Officer
- Geoffrey Porges – Executive Vice President and Chief Financial Officer
- Karen Akinsanya – President, Research and Development
- Murat Tunaboylu – Chief Commercial Officer
- Samuel L. Broder – Chief Medical Officer
The leadership philosophy emphasizes long-term value creation through scientific rigor, platform scalability, and disciplined capital allocation, with governance practices aligned to U.S. public company standards and oversight by an independent board of directors.